Vol. 5 No. 11 (2025)
Reimbursement Reviews

Belzutifan (Welireg)

decorative image of the issue cover

Published November 14, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses belzutifan (Welireg), 40 mg, tablets, oral.
  • Indication: For the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI.